High platelet × C-reactive protein level multiplier is a negative prognostic marker in rectal cancer treated by neoadjuvant chemoradiotherapy.
Chemoradiotherapy
Local advanced rectal cancer
Platelet count × C-reactive protein level multiplier
Prognosis
Rectal cancer
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
27
08
2020
accepted:
14
12
2020
pubmed:
9
1
2021
medline:
24
3
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
The clinical significance of the platelet count × C-reactive protein level multiplier (P-CRP) in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy followed by curative surgery has not been fully evaluated. In this retrospective study, the correlation between the P-CRP and prognosis was evaluated in 135 patients with LARC. We also performed a subgroup analysis limited to patients with pathological TNM stage III [ypN(+)] LARC. The cut-off value of the P-CRP for prognosis was set at 4.11. The high and low P-CRP groups comprised 39 (28.89%) and 96 (71.11%) patients, respectively. Among the investigated clinicopathological factors, the serum carcinoembryonic antigen level and presence of recurrence were significantly associated with the P-CRP value. In the Kaplan-Meier analysis, both overall survival (OS) and disease-free survival (DFS) were shorter in the high P-CRP group (p < 0.0001 and p = 0.0002, respectively; log-rank test). Multivariate analysis using a Cox proportional hazards model showed that a high P-CRP was an independent prognostic factor for OS [hazard ratio (HR) 29.20; 95% confidence interval (CI), 3.42-294.44; p = 0.0024] and DFS (HR 5.89; 95%CI 1.31-22.69; p = 0.023) in patients with LARC. In addition, a high P-CRP predicted poor OS and DFS in patients with pathological TNM stage III [ypN(+)] LARC (p = 0.0001 and p = 0.0012, respectively; log-rank test). The P-CRP is a promising predictor of survival and recurrence in patients with LARC treated by neoadjuvant chemoradiotherapy followed by curative surgery.
Identifiants
pubmed: 33415573
doi: 10.1007/s10147-020-01857-w
pii: 10.1007/s10147-020-01857-w
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
708-716Références
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
doi: 10.1056/NEJMoa040694
Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
doi: 10.1056/NEJMoa060829
Park IJ, You YN, Agarwal A et al (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770–1776
doi: 10.1200/JCO.2011.39.7901
Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701
doi: 10.1097/01.sla.0000257358.56863.ce
Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444
doi: 10.1038/nature07205
Tada N, Tsuno NH, Kawai K et al (2014) Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients. Oncol Rep 31:463–471
doi: 10.3892/or.2013.2857
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163
doi: 10.2217/fon.09.136
Miyamoto R, Oda T, Hashimoto S et al (2017) Platelet x CRP multiplier value as an indicator of poor prognosis in patients with resectable pancreatic cancer. Pancreas 46:35–41
doi: 10.1097/MPA.0000000000000697
Saito H, Kono Y, Murakami Y et al (2018) Prognostic significance of platelet-based inflammatory indicators in patients with gastric cancer. World J Surg 42:2542–2550
doi: 10.1007/s00268-018-4527-8
Shishido Y, Saito H, Shimizu S et al (2020) Prognostic significance of platelet x C-reactive protein multiplier in patients with esophageal squamous cell carcinoma. Surg Today 50:185–192
doi: 10.1007/s00595-019-01865-y
Yoshikawa R, Kusunoki M, Yanagi H et al (2001) Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029–1037
pubmed: 11221829
Inoue Y, Okigami M, Kawamoto A et al (2013) Phase I study of 5-fluorouracil, leucovorin and bevacizumab in combination with radiation therapy in patients with locally advanced rectal cancer. Mol Clin Oncol 1:511–516
doi: 10.3892/mco.2013.78
Wu Y, Li C, Zhao J et al (2016) Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol 14:289
doi: 10.1186/s12957-016-1044-9
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
doi: 10.1016/S0140-6736(00)04046-0
Canna K, Hilmy M, McMillan DC et al (2008) The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis 10:663–667
doi: 10.1111/j.1463-1318.2007.01416.x
Canna K, McArdle PA, McMillan DC et al (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651–654
doi: 10.1038/sj.bjc.6602419
Morris-Stiff G, Gomez D, Prasad KR (2008) C-reactive protein in liver cancer surgery. Eur J Surg Oncol 34:727–729
doi: 10.1016/j.ejso.2008.01.016
Proctor MJ, Morrison DS, Talwar D et al (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47:2633–2641
doi: 10.1016/j.ejca.2011.03.028
Roxburgh CS, Salmond JM, Horgan PG et al (2009) Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 249:788–793
doi: 10.1097/SLA.0b013e3181a3e738
Toiyama Y, Inoue Y, Saigusa S et al (2013) C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 33:5065–5074
pubmed: 24222151
Naschitz JE, Yeshurun D, Eldar S et al (1996) Diagnosis of cancer-associated vascular disorders. Cancer 77:1759–1767
doi: 10.1002/(SICI)1097-0142(19960501)77:9<1759::AID-CNCR1>3.0.CO;2-7
George ML, Eccles SA, Tutton MG et al (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147–3152
pubmed: 10955796
Gunsilius E, Petzer A, Stockhammer G et al (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58:169–174
doi: 10.1159/000012095
Imai T, Koike K, Kubo T et al (1991) Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78:1969–1974
doi: 10.1182/blood.V78.8.1969.1969
Ruscetti FW (1994) Hematologic effects of interleukin-1 and interleukin-6. Curr Opin Hematol 1:210–215
pubmed: 9371284
Mohle R, Green D, Moore MA et al (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94:663–668
doi: 10.1073/pnas.94.2.663
Troxler M, Dickinson K, Homer-Vanniasinkam S (2007) Platelet function and antiplatelet therapy. Br J Surg 94:674–682
doi: 10.1002/bjs.5852
Garcia VM, Batlle JF, Casado E et al (2011) Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 13:989–998
doi: 10.1111/j.1463-1318.2010.02386.x
Toiyama Y, Inoue Y, Kawamura M et al (2015) Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg 100:199–207
doi: 10.9738/INTSURG-D-13-00178.1
Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820
doi: 10.1016/S0140-6736(09)60484-0
Boustani J, Caubet M, Bosset JF (2016) Adjuvant chemotherapy in rectal cancer after chemoradiotherapy. Clin Oncol (R Coll Radiol) 28:140–145
doi: 10.1016/j.clon.2015.11.004
Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190
doi: 10.1016/S1470-2045(13)70599-0
Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25:1356–1362
doi: 10.1093/annonc/mdu147
Wang X, Yu Y, Meng W et al (2018) Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial. Radiother Oncol 129:300–305
doi: 10.1016/j.radonc.2018.08.027
Petrelli F, Trevisan F, Cabiddu M et al (2020) Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 271:440–448
doi: 10.1097/SLA.0000000000003471
Goodman KA (2018) Total neoadjuvant therapy for rectal cancer. Cancer Radiother 22:459–465
doi: 10.1016/j.canrad.2018.01.004
Benson AB, Venook AP, Al-Hawary MM et al (2018) Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(7):874–901. https://doi.org/10.6004/jnccn.2018.0061
doi: 10.6004/jnccn.2018.0061